NIH plans to slash support for indirect research costs, sending shockwaves through science
The NIH said Friday night that it would slash support for indirect costs on all existing and future grants to 15%
Related Articles
How I treat blastic plasmacytoid dendritic cell neoplasm
Blastic plasmacytoid dendritic cell neoplasm is a rare but aggressive malignancy that arises from precursors of plasmacytoid dendritic cells and typically
Dozens of Clinical Trials Have Been Frozen in Response to Trump’s USAID Order
The stop-work order on U.S.A.I.D.-funded research has left thousands of people with experimental drugs and devices in their bodies, with no access to monitoring or…
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
PURPOSESWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly…
Institutional Facts and Rates – UW Research
Institutional codes, numbers, facts, & rates for UW research such as Benefit Rates, F&A Rates, Contacts & Mailing Address, Annual Report, and more…
NIH plans to slash support for indirect research costs, sending shockwaves through science
The NIH said Friday night that it would slash support for indirect costs on all existing and future grants to 15%
The dark zone of CNS relapse in DLBCL
In this issue of Blood, Alduaij and colleagues report on central nervous system (CNS) relapse rates in a retrospective cohort of patients with high-grade B
LungMAP – Home
We are extremely grateful to the families who have generously given such precious gifts to support this important research.
Class action suit over UnitedHealth’s AI care denials nears key moment
A ruling may come this month on UnitedHealth’s motion to dismiss a lawsuit stemming from STAT reporting on the firm’s use of AI to cut…
The User’s Guide to Amivantamab
Targeted Oncology – Targeted therapies have revolutionized treatment of non-small-cell lung cancer (NSCLC); however, epidermal growth factor receptor (EGFR) exon20ins mutations are resistant to…